

**IN THE CLAIMS**

Please amend the claims as follows:

86. (Previously Presented) A therapeutic method for treating a bone-associated cancer comprising:

- (a) hydrating said cancer patient by administration of water;
- (b) parenterally administering a dose of  $^{166}\text{Ho}$ -DOTMP to said patient in an aqueous vehicle comprising an effective antiradiolytic amount of a pharmaceutically acceptable radioprotectant, said dose being effective to deliver about 20-60 Gy to the bone marrow of said patient;
- (c) administering a dose of at least about 200 mg/m<sup>2</sup> melphalan to the patient; and
- (d) providing the patient with an autologous stem cell transplant;

wherein the patient is not subjected to total body irradiation in conjunction with the therapeutic method.

87. (Previously Presented) The method of claim 86 wherein the cancer is multiple myeloma.

88. (Previously Presented) The method of claim 86 wherein the cancer is metastatic breast or prostate cancer.

89. (Previously Presented) The method of claim 86 wherein the cancer is Ewing's sarcoma.

90. (Previously Presented) The method of claim 86, 87 or 88 wherein the radioprotectant is ascorbic acid or gentisic acid.

91. (Previously Presented) The method of claim 90 wherein the concentration of ascorbic acid is about 35-75 mg/ml.

92. (Previously Presented) The method of claim 91 wherein the vehicle is buffered to about pH 7-8.

93. (Previously Presented) The method of claim 90 wherein the dose is effective to deliver about 20-30 Gy to the bone marrow of said patient.

94-99. (Canceled).

100. (Currently Amended) A liquid pharmaceutical composition comprising  $^{166}\text{Ho}$  complexed with 1,4,7,10-tetraazacyclododecanetetramethylene-phosphonic acid (DOTMP) and an effective antiradiolytic amount of a pharmaceutically acceptable ~~radioprotectant~~ radioprotectant selected from the group consisting of ascorbic acid or gentisic acid.

101. (Canceled).

102. (Currently Amended) The composition of claim ~~101~~ 100 comprising about 35-75 mg ascorbic acid/ml of composition.

103. (Currently Amended) The composition of claim 100 or ~~101~~ 102 wherein the ratio of DOTMP to  $^{166}\text{Ho}$  is above 3.

104. (Previously Presented) The composition of claim 100, comprising an aqueous carrier adjusted to pH 7-8.

105. (Currently Amended) The composition of claim 100 which is stable for at least ~~72~~ 48 hours under ambient conditions.